Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2024

Share-Based Payment Arrangement [Abstract]

Schedule of share option activity and related information for employees and directors

The following is a summary of the Company’s stock option activity under the 2014 Plan and the 2023 Plan for the three months ended March 31, 2024:

($ in thousands, except share and per share data)	Stock Options			Weighted- Average Exercise Price		Weighted-Average Remaining Contractual Life (in years)		Aggregate Intrinsic Value
Outstanding at December 31, 2023		651,237,400		$	0.01		8.5	$	—
Granted		—			—
Exercised		—			—
Forfeited		—			—
Expired		(24,500,000	)		0.02
Outstanding at March 31, 2024 (1)		626,737,400		$	0.01		8.4	$	—
Exercisable at March 31, 2024		236,434,688		$	0.01		7.9	$	—

___________

(1)Includes both vested stock options as well as unvested stock options for which the requisite service period has not been rendered but that are expected to vest based on achievement of a service condition.

Schedule of assumptions used to determine the fair value of stock granted

The weighted-average assumptions that the Company used to determine the fair value of share options granted were as follows, presented on a weighted average basis:

	2024		2023
Expected volatility		—		98.1	%
Risk-free interest rate		—		4.1	%
Expected dividend yield		—		—
Expected term (in years)		—		5.5

Summary of activity of the Company's unvested RSUs

The following table summarizes the Company’s restricted stock activity for the three months ended March 31, 2024:

	Time-based Awards
($ in thousands, except per share data)	Number of Shares			Weighted-Average Grant Date Fair Value
Nonvested shares at December 31, 2023		385,954,925		$	0.00
Granted		—			—
Forfeited		—			—
Vested		(97,578,000	)		0.00
Nonvested shares at March 31, 2024		288,376,925		$	0.00

Schedule of stock-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss

Total share-based compensation expense attributable to share-based payments made to employees, consultants and directors included in operating expenses in the Company's condensed consolidated statements of operations and comprehensive (loss) income for the three months ended March 31, 2024 and 2023, was as follows:

	Three Months Ended
	March 31,
($ in thousands)	2024		2023
Research and development	$	43	$	31
General and administrative		253		234
Total share-based compensation expense	$	296	$	265